Literature DB >> 19718798

Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer.

Lin Yang1, Hu Zhang, Momir Mikov, Ian G Tucker.   

Abstract

Bile salts are endogenous surfactants which have been widely used in drug formulation and drug delivery systems to increase drug permeation. When given by subcutaneous injection to rats, the novel bile salt, monoketocholate (MKC) has been shown to increase brain uptake of several drugs. This study aimed to characterize the physicochemical and some biological properties of MKC as a basis for understanding the mechanism by which it enhances membrane permeability. Comparison was made with three natural bile salts, cholate, deoxycholate and taurocholate. Critical micelle concentrations (CMC) were measured by the surface tension method and partition coefficients in n-octanol/buffer were measured by liquid-liquid extraction. The effects of bile salts on three different biological membrane models were investigated. Penetration studies in Langmuir monolayers indicated that MKC has only a weak ability to insert into phospholipid monolayers, but it can increase their elasticity once incorporated. In the erythrocyte model, MKC did not cause hemolysis at concentrations up to 10 mM, but changed the deformability of erythrocytes. Studies of the permeability of mannitol and transepithelial electrical resistance (TEER) across Caco-2 cell monolayers showed MKC did not cause significant increases in mannitol permeability or decreases in TEER values. In conclusion, MKC does not display strong membrane-solubilizing properties, but does change the mechanical properties of biological membranes. This effect might influence both passive and active transcellular permeation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718798     DOI: 10.1021/mp800143w

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

Review 1.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

2.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-28       Impact factor: 2.441

3.  Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.

Authors:  Armin Mooranian; Rebecca Negrulj; Hesham S Al-Sallami; Zhongxiang Fang; Momir Mikov; Svetlana Golocorbin-Kon; Marc Fakhoury; Gerald F Watts; Vance Matthews; Frank Arfuso; Amanda Lambros; Hani Al-Salami
Journal:  AAPS PharmSciTech       Date:  2014-08-29       Impact factor: 3.246

4.  Bile Acid Inhibition of N-type Calcium Channel Currents from Sympathetic Ganglion Neurons.

Authors:  Hye Kyung Lee; Kyoung Hwa Lee; Eui-Sic Cho
Journal:  Korean J Physiol Pharmacol       Date:  2012-02-28       Impact factor: 2.016

5.  The effect of hydroxyl moieties and their oxosubstitution on bile acid association studied in floating monolayers.

Authors:  Márta Szekeres; Béla Viskolcz; Mihalj Poša; János Csanádi; Dušan Škorić; Erzsébet Illés; Ildikó Y Tóth; Etelka Tombácz
Journal:  ScientificWorldJournal       Date:  2014-12-25

6.  Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.

Authors:  Mladena Lalić-Popović; Velibor Vasović; Boris Milijašević; Svetlana Goločorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  J Diabetes Res       Date:  2013-03-13       Impact factor: 4.011

7.  Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.

Authors:  Armin Mooranian; Rebecca Negrulj; Sangeetha Mathavan; Jorge Martinez; Jessica Sciarretta; Nigel Chen-Tan; Tk Mukkur; Momir Mikov; Mladena Lalic-Popovic; Maja Stojančević; Svetlana Golocorbin-Kon; Hani Al-Salami
Journal:  J Pharm Innov       Date:  2014       Impact factor: 2.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.